<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MYCAMINE- micafungin sodium injection, powder, lyophilized, for solution </strong><br>Astellas Pharma US, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use MYCAMINE<span class="Sup">®</span> safely and effectively. See Full Prescribing Information for MYCAMINE.<br><br>MYCAMINE (micafungin sodium) For Injection; IV Infusion Only<br>Initial U.S. Approval: 2005<br><br>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Indications and Usage (<a href="#i4i_indications_id_90c52805-4f91-4d78-bff3-7a3713211a37">1</a>)                                                06/2013<br>Dosage and Administration (<a href="#i4i_dosage_admin_id_e0bf5887-433d-444c-878c-e24214e01145">2</a>)                                        06/2013 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Mycamine is an echinocandin indicated in adult and pediatric patients 4 months and older for: </p>
<dl>
<dt>•</dt>
<dd>Treatment of Patients with <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span>, Acute <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Disseminated Candidiasis</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">Peritonitis</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscesses</span> (<a href="#i4i_section_id_a3dc6c4a-0d79-4b8f-8d4b-c7667196a6aa">1.1</a>)</dd>
<dt>•</dt>
<dd>Treatment of Patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span> (<a href="#i4i_section_id_bf9236dd-e777-46dd-89f1-8b3dd23ca9ec">1.2</a>)</dd>
<dt>•</dt>
<dd>Prophylaxis of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Patients Undergoing Hematopoietic Stem Cell Transplantation (<a href="#i4i_section_id_84f5016d-4807-46ac-97ce-bcc652f7db1f">1.3</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><br><span class="Bold">Recommended Reconstituted Dose Once Daily By Indication</span> </p>
<table width="100%">
<col width="37%">
<col width="33%">
<col width="14%">
<col width="16%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="middle"><p class="Highlighta"><span class="Bold">Indication</span> </p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle"><p class="Highlighta"><span class="Bold">Dose</span> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="Highlighta"><span class="Bold">Adult</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="Highlighta"><span class="Bold">Pediatric 30 kg or less</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="Highlighta"><span class="Bold">Pediatric greater than </span><br><span class="Bold">30 kg</span> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="Highlighta">Treatment of <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span>, Acute <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Disseminated Candidiasis</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">Peritonitis</span> and Abscesses (<a href="#i4i_section_id_a3dc6c4a-0d79-4b8f-8d4b-c7667196a6aa">1.1</a>) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="Highlighta">100 mg daily </p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><p class="Highlighta">2 mg/kg/day<br>(maximum 100 mg daily) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="Highlighta">Treatment of <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span> (<a href="#i4i_section_id_bf9236dd-e777-46dd-89f1-8b3dd23ca9ec">1.2</a>) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="Highlighta">150 mg daily </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="Highlighta">3 mg/kg/day </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="Highlighta">2.5 mg/kg/day<br>(maximum150 mg daily) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="Highlighta">Prophylaxis of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in HSCT Recipients (<a href="#i4i_section_id_84f5016d-4807-46ac-97ce-bcc652f7db1f">1.3</a>) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="Highlighta">50 mg daily </p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><p class="Highlighta">1 mg/kg/day<br>(maximum 50 mg daily) </p></td>
</tr>
</tbody>
</table>
<p class="Highlighta">A loading dose is not required. Infuse over 1 hour. (<a href="#i4i_section_id_5f7610c7-b20a-4a3e-9a72-924c121ec509">2.1</a>, <a href="#i4i_section_id_3b8ec8f6-38fb-40fc-be21-ecbeb91c29b8">2.4</a>) </p>
<p class="Highlighta">See Full Prescribing Information for IV administration instructions (<a href="#i4i_dosage_admin_id_e0bf5887-433d-444c-878c-e24214e01145">2</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">50 mg and 100 mg single-use vials (<a href="#i4i_dosage_form_strength_id_79ea833b-a15e-4b52-ae73-14a477909f9e">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Mycamine is contraindicated in persons with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to micafungin sodium, any component of Mycamine, or other echinocandins. (<a href="#i4i_contraindications_id_4c20c5b8-633f-4536-856c-94d00a75c4ef">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> </p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> (including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>) have been observed. Discontinue Mycamine and administer appropriate treatment (<a href="#i4i_section_id_439f0348-96d9-45e5-800f-a6be72a071db">5.1</a>)</dd>
</dl>
<p class="Highlighta">Hematological Effects </p>
<dl>
<dt>•</dt>
<dd>Isolated cases of acute <span class="product-label-link" type="condition" conceptid="4049138" conceptname="Intravascular hemolysis">intravascular hemolysis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> and <span class="product-label-link" type="condition" conceptid="321414" conceptname="Hemoglobinuria">hemoglobinuria</span> have been reported (<a href="#i4i_section_id_bcad80b7-105e-4270-b754-48ff426f9bfa">5.2</a>)</dd>
</dl>
<p class="Highlighta">Hepatic Effects </p>
<dl>
<dt>•</dt>
<dd>Abnormalities in liver function tests; isolated cases of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have been observed (<a href="#i4i_section_id_6da964ec-5258-42eb-9b48-27df2dcb6761">5.3</a>)</dd>
</dl>
<p class="Highlighta">Renal Effects </p>
<dl>
<dt>•</dt>
<dd>Elevations in BUN and creatinine; isolated cases of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been reported (<a href="#i4i_section_id_8ab940b2-e65c-4316-883c-34b39265b5ae">5.4</a>)</dd>
</dl>
<p class="Highlighta">Monitor closely patients who develop clinical or laboratory evidence of the above reactions and evaluate risk/benefit of continuing Mycamine therapy. (<a href="#i4i_warnings_precautions_id_5a7e098e-8583-42a1-8378-cf5556dcba56">5</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>Most common adverse reactions include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (<a href="#i4i_adverse_effects_id_8383637c-52d9-4ecc-acf8-86cf86fabb1b">6</a>)</dd>
<dt>•</dt>
<dd>Histamine-mediated symptoms including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>, and <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> (<a href="#i4i_section_id_8e50fbb7-ae85-4ac0-8482-f1199490f26e">6.1</a>)</dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact: Astellas Pharma US, Inc. at 1-800-727-7003 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a>. </span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Monitor for sirolimus, itraconazole or nifedipine toxicity, and dosage of sirolimus, itraconazole or nifedipine should be reduced, if necessary (<a href="#i4i_interactions_id_8092a9e4-3fdc-4b0d-8201-8b6754a0acba">7</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy - No human data. Adverse effects in animals. Use if potential benefits of treatment outweigh potential fetal risk (<a href="#i4i_pregnancy_id_dadbdba4-b44c-460f-8bff-8b2f16d3cbce">8.1</a>)</dd>
<dt>•</dt>
<dd>Nursing Mothers - Caution should be exercised if administered to a nursing woman (<a href="#i4i_nursing_mothers_id_cc80daf1-46a1-493b-93c3-3c8793634103">8.3</a>)</dd>
<dt>•</dt>
<dd>Safety and effectiveness in pediatric patients less than 4 months of age have not been established (<a href="#i4i_pediatric_use_id_8a7875b6-07a6-4570-8f82-13f472e6c516">8.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="XmChange">1 INDICATIONS AND USAGE</span></a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Treatment of Patients with <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span>, Acute <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Disseminated Candidiasis</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">Peritonitis</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscesses</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Treatment of Patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Prophylaxis of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Patients Undergoing Hematopoietic Stem Cell Transplantation</a></h2>
<h1><a href="#section-2" class="toc"><span class="XmChange">2 DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="XmChange">2.1 Dose and Schedule for Adults</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="XmChange">2.2 Dose and Schedule for Pediatric Patients</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="XmChange">2.3 Directions for Reconstitution, Dilution, and Preparation</span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="XmChange">2.4 Infusion Volume and Duration</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Hematological Effects</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Hepatic Effects</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Renal Effects</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Infusion Reactions</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trials Experience in Adults</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Clinical Trials Experience in Pediatric Patients </a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Postmarketing Adverse Reactions</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Race and Gender</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-12.3" class="toc">12.4 Microbiology </a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-13.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Adult Treatment of <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span> and Other <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-14.2" class="toc">14.2 Adult Treatment of <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span></a></h2>
<h2><a href="#section-14.3" class="toc">14.3 Prophylaxis of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Hematopoietic Stem Cell Transplant Recipients</a></h2>
<h1><a href="#section-15" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-16" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-17" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_90c52805-4f91-4d78-bff3-7a3713211a37"></a><a name="section-1"></a><p></p>
<h1 style="border-left:1px solid;"><span class="XmChange">1 INDICATIONS AND USAGE</span></h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Mycamine<span class="Sup">®</span> is indicated in adult and pediatric patients 4 months and older for:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a3dc6c4a-0d79-4b8f-8d4b-c7667196a6aa"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Treatment of Patients with <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span>, Acute <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Disseminated Candidiasis</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">Peritonitis</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscesses</span></h2>
<p class="First"><span class="Italics">[see <a href="#i4i_clinical_studies_id_71ef6c36-4269-45a3-be76-975f330b8599">Clinical Studies</a> (<a href="#i4i_section_id_c1c6d5d8-ba62-4a0b-b50c-2bcf0f716923">14.1</a>)].</span></p>
<p>Mycamine has not been adequately studied in patients with <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span>, <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span> and <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> due to <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bf9236dd-e777-46dd-89f1-8b3dd23ca9ec"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Treatment of Patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span></h2>
<p class="First"><span class="Italics">[see <a href="#i4i_clinical_studies_id_71ef6c36-4269-45a3-be76-975f330b8599">Clinical Studies</a> (<a href="#i4i_section_id_578d63b9-45e3-4f00-874c-0463c80da820">14.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_84f5016d-4807-46ac-97ce-bcc652f7db1f"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Prophylaxis of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Patients Undergoing Hematopoietic Stem Cell Transplantation</h2>
<p class="First"><span class="Italics">[see <a href="#i4i_clinical_studies_id_71ef6c36-4269-45a3-be76-975f330b8599">Clinical Studies</a> (<a href="#i4i_section_id_a22a0a17-c5d1-49d1-ae19-66542003a8d8">14.3</a>)].</span></p>
<p><span class="Bold">NOTE: The efficacy of Mycamine against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by fungi other than <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> has not been established.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_e0bf5887-433d-444c-878c-e24214e01145"></a><a name="section-2"></a><p></p>
<h1 style="border-left:1px solid;"><span class="XmChange">2 DOSAGE AND ADMINISTRATION</span></h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Do not mix or co-infuse Mycamine with other medications. Mycamine has been shown to precipitate when mixed directly with a number of other commonly used medications.<br>The recommended doses for adult patients based on indications are shown in</span> <a href="#table1">Table 1</a><span class="XmChange">.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5f7610c7-b20a-4a3e-9a72-924c121ec509"></a><a name="section-2.1"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.1 Dose and Schedule for Adults</span></h2>
<a name="table1"></a><table width="100%">
<caption><span>Table 1. Mycamine Dosage in Adult Patients</span></caption>
<col width="64%">
<col width="36%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>In patients treated successfully for <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> and other <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the mean duration of treatment was 15 days (range 10-47 days).</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>In patients treated successfully for <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>, the mean duration of treatment was 15 days (range 10-30 days).</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>In hematopoietic stem cell transplant (HSCT) recipients who experienced success of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy, the mean duration of prophylaxis was 19 days (range 6-51 days). </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First"><span class="Bold">Indication</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Recommended Reconstituted Dose Once Daily</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Treatment of <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span>, Acute <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Disseminated Candidiasis</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">Peritonitis</span> and <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscesses</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">100 mg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Treatment of <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">150 mg</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Prophylaxis of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in HSCT Recipients<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">50 mg</span></p></td>
</tr>
</tbody>
</table>
<p class="First">A loading dose is not required. Typically, 85% of the steady-state concentration is achieved after three daily Mycamine doses.</p>
<p>No dosing adjustments are required based on race, gender, or in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or in patients with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#i4i_specific_populations_id_ef7ab1e9-4e17-418f-8b10-fbb83fa0e668">Use in Specific Populations</a> (<a href="#i4i_specific_populations_id_ef7ab1e9-4e17-418f-8b10-fbb83fa0e668">8</a>)]</span>. </p>
<p>No dose adjustment for Mycamine is required with concomitant use of mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, voriconazole, itraconazole, amphotericin B, ritonavir, or rifampin <span class="Italics">[see <a href="#i4i_interactions_id_8092a9e4-3fdc-4b0d-8201-8b6754a0acba">Drug Interactions</a> (<a href="#i4i_interactions_id_8092a9e4-3fdc-4b0d-8201-8b6754a0acba">7</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_64f3b8f5-3792-4e56-b1bc-fdce8b0606ef"></a><a name="section-2.2"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.2 Dose and Schedule for Pediatric Patients</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The recommended doses for pediatric patients based on indication and weight are shown in <a href="#_Refid_65dd214b-9db4-454b-b533-232372983">Table 2</a>.</span></p>
<a name="_Refid_65dd214b-9db4-454b-b533-232372983"></a><table width="100%">
<caption><span>Table 2. Mycamine Dosage in Pediatric Patients 4 months or older</span></caption>
<col width="43%">
<col width="26%">
<col width="1%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="middle"><p class="First"><span class="Bold">Indication</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="middle"><p class="First"><span class="Bold">Pediatric Dose Given Once Daily</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">30 kg or less</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><p class="First"><span class="Bold">Greater than 30 kg</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span>, Acute <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Disseminated Candidiasis</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">Peritonitis</span> and Abscesses (<a href="#i4i_section_id_a3dc6c4a-0d79-4b8f-8d4b-c7667196a6aa">1.1</a>)</span></p></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="middle"><p class="First">2 mg/kg<br>(maximum daily dose 100 mg)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span> (<a href="#i4i_section_id_bf9236dd-e777-46dd-89f1-8b3dd23ca9ec">1.2</a>)</span></p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="middle"><p class="First">3 mg/kg</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2.5 mg/kg (maximum daily dose 150 mg)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Prophylaxis of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span></span> <span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in HSCT Recipients (<a href="#i4i_section_id_84f5016d-4807-46ac-97ce-bcc652f7db1f">1.3</a>)</span></p></td>
<td class="Botrule Rrule" align="center" colspan="3" valign="middle"><p class="First">1 mg/kg<br>(maximum daily dose 50 mg)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_24c4a368-986b-49ef-89e6-2e2722db301a"></a><a name="section-2.3"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.3 Directions for Reconstitution, Dilution, and Preparation</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Please read this entire section carefully before beginning reconstitution.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="Underline">Reconstitution</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">Reconstitute Mycamine vials by aseptically adding 5 mL of one of the following compatible solutions:</span></p>
<dl>
<dt>•</dt>
<dd><span class="XmChange">0.9% Sodium Chloride Injection, USP (without a bacteriostatic agent). </span></dd>
<dt>•</dt>
<dd><span class="XmChange">5% Dextrose Injection, USP</span></dd>
</dl>
<p style="border-left:1px solid;"><span class="XmChange">To minimize excessive foaming, <span class="Bold">Gently</span> dissolve the Mycamine powder by swirling the vial. Do <span class="Bold">Not</span> Vigorously Shake The Vial. Visually inspect the vial for particulate matter.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Mycamine 50 mg vial:</span> after reconstitution <span class="Bold">each mL contains 10 mg of micafungin sodium.</span><br><span class="Bold">Mycamine 100 mg vial:</span> after reconstitution <span class="Bold">each mL contains 20 mg of micafungin sodium.</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">As with all parenteral drug products, reconstituted Mycamine should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use material if there is any evidence of precipitation or foreign matter. Aseptic technique must be strictly observed in all handling since no preservative or bacteriostatic agent is present in Mycamine or in the materials specified for reconstitution and dilution.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics"><span class="Underline">Dilution and Preparation</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">The diluted solution should be protected from light. It is not necessary to cover the infusion drip chamber or the tubing. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Adult Patients:</span></p>
<dl>
<dt>1.</dt>
<dd><span class="XmChange">Add the appropriate volume of reconstituted Mycamine into 100 mL of 0.9% Sodium Chloride Injection, USP or 100 mL of 5% Dextrose Injection, USP.</span></dd>
<dt>2.</dt>
<dd><span class="XmChange">Appropriately label the bag.</span></dd>
</dl>
<p style="border-left:1px solid;"><span class="XmChange">Pediatric Patients:</span></p>
<dl>
<dt>1.</dt>
<dd><span class="XmChange">Calculate the total Mycamine dose in milligrams (mg) by multiplying the recommended pediatric dose (mg/kg) for a given indication <span class="Italics">[see <a href="#_Refid_65dd214b-9db4-454b-b533-232372983">Table 2</a>]</span> and the weight of the patient in kilograms (kg).</span></dd>
<dt>2.</dt>
<dd><span class="XmChange">To calculate the volume (mL) of drug needed, divide the calculated dose (mg) from step 1 by the final concentration of the selected reconstituted vial(s) (either 10 mg/mL for the 50 mg vial <span class="Bold">or</span> 20 mg/mL for the 100 mg vial), see example below:<br><br><span class="Bold"><span class="Underline">Using 50 mg vials:</span></span><br>Divide the calculated mg dose (from step 1) by <span class="Bold">10 mg/mL</span> to determine the volume (mL) needed.<br><span class="Bold">                                                                   OR</span><br><span class="Bold"><span class="Underline">Using 100 mg vials:</span></span><br>Divide the calculated mg dose (from step 1) by <span class="Bold">20 mg/mL</span> to determine the volume (mL) needed.<br><br></span></dd>
<dt>3.</dt>
<dd><span class="XmChange">Withdraw the calculated volume (mL) of drug needed from the selected concentration and size of reconstituted Mycamine vial(s) used in Step 2 (ensure the selected concentration and vial size used to calculate the dose is also used to prepare the infusion).</span></dd>
<dt>4.</dt>
<dd><span class="XmChange">Add the withdrawn volume of drug (step 3) to a 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP intravenous infusion bag or syringe. Ensure that the final concentration of the solution is between 0.5 mg/mL to 4 mg/mL. <br><br><span class="Bold">Note:</span> To minimize the risk of infusion reactions, concentrations of greater than 1.5 mg/mL should be administered via central catheter <span class="Italics">[see <a href="#i4i_adverse_effects_id_8383637c-52d9-4ecc-acf8-86cf86fabb1b">Adverse Reactions</a> (<a href="#i4i_section_id_8e50fbb7-ae85-4ac0-8482-f1199490f26e">6.1</a>)]</span>.<br><br></span></dd>
<dt>5.</dt>
<dd><span class="XmChange">Appropriately label the infusion bag or syringe. For concentrations above 1.5 mg/mL, if required, label to specifically warn to administer the solution via central catheter.</span></dd>
</dl>
<p style="border-left:1px solid;"><span class="XmChange">Mycamine is preservative-free. Discard partially used vials.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3b8ec8f6-38fb-40fc-be21-ecbeb91c29b8"></a><a name="section-2.4"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.4 Infusion Volume and Duration</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Mycamine should be administered by intravenous infusion only. Infuse over one hour. More rapid infusions may result in more frequent histamine mediated reactions.</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Bold">An existing intravenous line should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with 0.9% Sodium Chloride Injection, USP, prior to infusion of Mycamine. </span></span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Italics">Pediatric Patients</span><br>Mycamine should be infused over one hour. To minimize the risk of infusion reactions, concentrations of greater than 1.5 mg/mL should be administered via central catheter <span class="Italics">[see <a href="#i4i_adverse_effects_id_8383637c-52d9-4ecc-acf8-86cf86fabb1b">Adverse Reactions</a> (<a href="#i4i_section_id_8e50fbb7-ae85-4ac0-8482-f1199490f26e">6.1</a>)].</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_79ea833b-a15e-4b52-ae73-14a477909f9e"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">50 mg and 100 mg single-use vials</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_4c20c5b8-633f-4536-856c-94d00a75c4ef"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Mycamine is contraindicated in persons with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to micafungin, any component of Mycamine, or other echinocandins.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_5a7e098e-8583-42a1-8378-cf5556dcba56"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_439f0348-96d9-45e5-800f-a6be72a071db"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Isolated cases of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and anaphylactoid) reactions (including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>) have been reported in patients receiving Mycamine. If these reactions occur, Mycamine infusion should be discontinued and appropriate treatment administered. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bcad80b7-105e-4270-b754-48ff426f9bfa"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Hematological Effects</h2>
<p class="First">Acute <span class="product-label-link" type="condition" conceptid="4049138" conceptname="Intravascular hemolysis">intravascular hemolysis</span> and <span class="product-label-link" type="condition" conceptid="321414" conceptname="Hemoglobinuria">hemoglobinuria</span> was seen in a healthy volunteer during infusion of Mycamine (200 mg) and oral prednisolone (20 mg). This reaction was transient, and the subject did not develop significant <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Isolated cases of significant <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> and <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> have also been reported in patients treated with Mycamine. Patients who develop clinical or laboratory evidence of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> or <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> during Mycamine therapy should be monitored closely for evidence of worsening of these conditions and evaluated for the risk/benefit of continuing Mycamine therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6da964ec-5258-42eb-9b48-27df2dcb6761"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Hepatic Effects</h2>
<p class="First">Laboratory abnormalities in liver function tests have been seen in healthy volunteers and patients treated with Mycamine. In some patients with serious underlying conditions who were receiving Mycamine along with multiple concomitant medications, clinical hepatic abnormalities have occurred, and isolated cases of significant <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have been reported. Patients who develop <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> during Mycamine therapy should be monitored for evidence of worsening hepatic function and evaluated for the risk/benefit of continuing Mycamine therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ab940b2-e65c-4316-883c-34b39265b5ae"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Renal Effects</h2>
<p class="First">Elevations in BUN and creatinine, and isolated cases of significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> have been reported in patients who received Mycamine. In fluconazole-controlled trials, the incidence of drug-related renal adverse reactions was 0.4% for Mycamine treated patients and 0.5% for fluconazole treated patients. Patients who develop abnormal renal function tests during Mycamine therapy should be monitored for evidence of worsening renal function. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_8383637c-52d9-4ecc-acf8-86cf86fabb1b"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The overall safety of Mycamine was assessed in 3227 adult and pediatric patients and 520 volunteers in 46 clinical trials, including the <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">invasive candidiasis</span>, <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span> and prophylaxis trials, who received single or multiple doses of Mycamine, ranging from 0.75 mg/kg to 10 mg/kg in pediatric patients and 12.5 mg to 150 mg/day or greater in adult patients.</p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of Mycamine cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does provide a basis for identifying adverse events that appear to be related to drug use and for approximating rates.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8e50fbb7-ae85-4ac0-8482-f1199490f26e"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Infusion Reactions</h2>
<p class="First">Possible histamine-mediated symptoms have been reported with Mycamine, including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>, and <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reactions</span>, including <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> have been reported, at Mycamine doses of 50-150 mg/day. These reactions tended to occur more often in patients receiving Mycamine via peripheral intravenous administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da6ac0a2-4195-44d7-acfe-8d8492e8c8b0"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trials Experience in Adults</h2>
<p class="First"><span class="Bold"><span class="Italics"> </span></span>In all clinical trials with Mycamine, 2497/2748 (91%) adult patients experienced at least one treatment-emergent adverse reaction.</p>
<p><span class="Bold"><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span> and Other <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span></span></p>
<p>In a randomized, double-blind study for treatment of <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> and other <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, treatment-emergent adverse reactions occurred in 183/200 (92%), 187/202 (93%) and 171/193 (89%) patients in the Mycamine 100 mg/day, Mycamine 150 mg/day, and caspofungin (a 70 mg loading dose followed by a 50 mg/day dose) treatment groups, respectively. Selected treatment-emergent adverse reactions, those occurring in 5% or more of the patients and more frequently in a Mycamine treatment group, are shown in <a href="#_Refid_ed6923c4-81e1-45fc-bc42-4ecd7ba8a">Table 3</a>. </p>
<a name="_Refid_ed6923c4-81e1-45fc-bc42-4ecd7ba8a"></a><table width="100%">
<caption><span>Table 3. Selected<span class="Sup">*</span> Treatment-Emergent Adverse Reactions in Adult Patients with <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span> and Other <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></caption>
<col width="48%">
<col width="19%">
<col width="19%">
<col width="15%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">Patient base: all randomized patients who received at least 1 dose of trial drug <br><span class="Sup">*</span> During IV treatment + 3 days<br><span class="Sup">¥</span> MedDRA v5.0<br><span class="Sup">†</span> Within a system organ class patients may experience more than 1 adverse reaction.<br><span class="Sup">‡</span> 70 mg loading dose on day 1 followed by 50 mg/day thereafter (caspofungin)</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">System Organ Class</span><span class="Sup">¥</span><br>(Preferred Term) <span class="Sup">†</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Mycamine 100 mg </span></p>
<p><span class="Bold">n (%)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Mycamine 150 mg </span></p>
<p><span class="Bold">n (%)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Caspofungin</span><span class="Sup">‡</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Number of Patients</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">200</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">202</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">193</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">81 (41)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">89 (44)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">76 (39)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">15 (8) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">26 (13) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">14 (7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">19 (10) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">15 (7) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">20 (10)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">18 (9) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">15 (7) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">16 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Metabolism and Nutrition Disorders </span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">77 (39)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">83 (41)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">73 (38)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">12 (6) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">14 (7) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">9 (5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">Hypernatremia</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 (4) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">13 (6) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 (4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">10 (5) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 (4) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">5 (3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">General Disorders/ Administration Site Conditions </span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">59 (30)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">56 (28)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">51 (26)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">14 (7) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">22 (11) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">15 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Investigations </span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">36 (18)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">49 (24)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">37 (19)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     Blood Alkaline Phosphatase Increased </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">11 (6) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">16 (8) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 (4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span> </span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">35 (18)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">48 (24)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">36 (19)</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">5 (3) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">10 (5) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>In a second, supportive, randomized, double-blind study for treatment of <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> and other <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, treatment-emergent adverse reactions occurred in 245/264 (93%) and 250/265 (94%) patients in the Mycamine (100 mg/day) and AmBisome (3 mg/kg/day) treatment groups, respectively. The following treatment-emergent adverse reactions in the Mycamine treated patients at least 16 years of age were notable: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (10% vs. 8%); <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (11% vs. 11%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (13% vs. 9%), <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span> (4% vs. 3%); increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (3% vs. 2%), and increased blood alkaline phosphatase (3% vs. 2%), in the Mycamine and AmBisome treatment groups, respectively.</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span></span></span></p>
<p>In a randomized, double-blind study for treatment of <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>, a total of 202/260 (78%) patients who received Mycamine 150 mg/day and 186/258 (72%) patients who received intravenous fluconazole 200 mg/day experienced an adverse reaction. Treatment-emergent adverse reactions resulting in discontinuation were reported in 17 (7%) Mycamine treated patients; and in 12 (5%) fluconazole treated patients. Selected treatment-emergent adverse reactions, those occurring in 5% or more of the patients and more frequently in the Mycamine group, are shown in <a href="#_Refid_e41cd8cb-a87a-476a-8f80-a6f97048e">Table 4</a>. </p>
<a name="_Refid_e41cd8cb-a87a-476a-8f80-a6f97048e"></a><table width="100%">
<caption><span>Table 4. Selected<span class="Sup">*</span> Treatment-Emergent Adverse Reactions in Adult Patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span></span></caption>
<col width="52%">
<col width="14%">
<col width="14%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="7" valign="top">Patient base: all randomized patients who received at least 1 dose of trial drug<br><span class="Sup">*</span> During treatment + 3 days.<br><span class="Sup">¥</span> MedDRA v5.0<br><span class="Sup">†</span> Within a system organ class patients may experience more than 1 adverse reaction.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First"><span class="Bold">System Organ Class</span><span class="Sup">¥</span><br>(Preferred Term)<span class="Sup"> †</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Mycamine</span></p>
<p><span class="Bold">150 mg/day</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Fluconazole</span></p>
<p><span class="Bold">200 mg/day</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Number of Patients</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">260</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">258</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">84 (32)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">93 (36)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">27 (10)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">29 (11)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">20 (8)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">23 (9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">17 (7)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">17 (7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">General Disorders/Administration Site Conditions </span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">52 (20)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">45 (17)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">34 (13)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">21 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">42 (16)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">40 (16)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">22 (9)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">20 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">54 (21)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">21 (8)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">49 (19)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">13 (5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">36 (14)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">26 (10)</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">14 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">6 (2)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics"><span class="Underline">Prophylaxis of <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Hematopoietic Stem Cell Transplant Recipients</span></span></span></p>
<p>A double-blind study was conducted in a total of 882 patients scheduled to undergo an autologous or allogeneic hematopoietic stem cell transplant. The median duration of treatment was 18 days (range 1 to 51 days) in both treatment arms. </p>
<p>All adult patients who received Mycamine (382) or fluconazole (409) experienced at least one adverse reaction during the study. Treatment-emergent adverse reactions resulting in Mycamine discontinuation were reported in 15 (4%) adult patients; while those resulting in fluconazole discontinuation were reported in 32 (8%). Selected adverse reactions, those reported in 15% or more of adult patients and more frequently on the Mycamine treatment arm, are shown in <a href="#_Refid_c4b60105-4ecf-44d0-a208-d0baa9063">Table 5</a>.</p>
<a name="_Refid_c4b60105-4ecf-44d0-a208-d0baa9063"></a><table width="100%">
<caption><span>Table 5. Selected Adverse Reactions in Adult Patients During Prophylaxis of <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> in Hematopoietic Stem Cell Transplant Recipients</span></caption>
<col width="42%">
<col width="13%">
<col width="14%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="10" valign="top">Patient base: all randomized adult patients who received at least 1 dose of trial drug<br><span class="Sup">¥</span> MedDRA v12.0<br><span class="Sup">† </span>Within a system organ class patients may experience more than 1 adverse reaction.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">System Organ Class</span><span class="Sup">¥</span><br>(Preferred Term) <span class="Sup">†</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Mycamine</span></p>
<p><span class="Bold">50 mg/day</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Fluconazole</span></p>
<p><span class="Bold">400 mg/day</span></p>
<p><span class="Bold">n (%)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Number of Patients</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First">382</p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First">409</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">377 (99)</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">404 (99)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">294 (77)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">327 (80)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">270 (71)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">290 (71)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">252 (66)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">274 (67)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">100 (26)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">93 (23)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Blood and Lymphatic System Disorders</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">368 (96)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">385 (94)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">     <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">288 (75)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">297 (73)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">     <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">286 (75)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">280 (69)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">257 (67)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">275 (67)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">95 (25)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">91 (22)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">250 (65)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">254 (62)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">169 (44)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">154 (38)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Psychiatric Disorders</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">233 (61)</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First"><span class="Bold">235 (58)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td class="Botrule Rrule" align="center"><p class="First">142 (37)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">140 (34)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">84 (22)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">87 (21)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">133 (35)</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">138 (34)</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">     <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">99 (26)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">91 (22)</p></td>
</tr>
</tbody>
</table>
<p>Other selected adverse reactions reported at less than 5% in adult clinical trials are listed below:</p>
<dl>
<dt>•</dt>
<dd>
<span class="Italics">Blood and lymphatic system disorders</span>: <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span></dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span>: <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4161701" conceptname="Pericardial effusion">pericardial effusion</span></dd>
<dt>•</dt>
<dd>
<span class="Italics">General disorders and administration site conditions</span>: infusion reaction, <span class="product-label-link" type="condition" conceptid="4318389" conceptname="Injection site thrombosis">injection site thrombosis</span></dd>
<dt>•</dt>
<dd>
<span class="Italics">Hepatobiliary disorders</span>: <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular damage</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span></dd>
<dt>•</dt>
<dd> <span class="Italics">Immune disorders</span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span></dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span></dd>
<dt>•</dt>
<dd>
<span class="Italics">Psychiatric disorders</span>: <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span></dd>
<dt>•</dt>
<dd>
<span class="Italics">Skin and subcutaneous tissue disorders</span>: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ea1b22ba-8f62-40f2-86c6-a88dd696c4c1"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Clinical Trials Experience in Pediatric Patients </h2>
<p class="First">The overall safety of Mycamine was assessed in 479 patients 3 days through 16 years of age who received at least one dose of Mycamine in 11 separate clinical studies. The mean treatment duration was 24.8 days. A total of 246 patients received at least one dose of Mycamine 2 mg/kg or higher.</p>
<p>Of the 479 pediatric patients, 264 (55%) were male, 319 (67%) were Caucasians, with the following age distribution: 116 (24%) less than 2 years, 108 (23%) between 2 and 5 years, 140 (29%) between 6 years and 11 years, and 115 (24%) between 12 and 16 years of age.</p>
<p>In all pediatric studies with Mycamine, 439/479 (92%) patients experienced at least one treatment-emergent adverse reaction.</p>
<p>Two studies that included pediatric patients were randomized, double-blind, and active-controlled: The <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">invasive candidiasis</span> and <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> study investigated the efficacy and safety of Mycamine (2 mg/kg/day for patients weighing 40 kg or less and 100 mg/day for patients weighing greater than 40 kg) compared to AmBisome (3 mg/kg/day) in 112 pediatric patients. Treatment-emergent adverse reactions occurred in 51/56 (91%) of patients in the Mycamine group and 52/56 (93%) of patients in the AmBisome group. Treatment-emergent adverse reactions resulting in Mycamine discontinuation were reported in 2 (4%) pediatric patients; while those resulting in AmBisome discontinuation were reported in 9 (16%).</p>
<p>The prophylaxis study in patients undergoing HSCT investigated the efficacy of Mycamine (1 mg/kg/day for patients weighing 50 kg or less and 50 mg/day for patients weighing greater than 50 kg) as compared to fluconazole (8 mg/kg/day for patients weighing 50 kg or less and 400 mg/day for patients weighing greater than 50 kg). All 91 pediatric patients experienced at least one treatment-emergent adverse reaction. Three (7%) pediatric patients discontinued Mycamine due to adverse reaction; while one (2%) patient discontinued fluconazole.</p>
<p>The selected treatment-emergent adverse reactions, those occurring in 15% or more of the patients and more frequently in a Mycamine group, for all Mycamine pediatric studies and for the two comparative studies (<span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> and prophylaxis) described above are shown in <a href="#_Refid_f7baebb2-7ce6-4245-a8c8-949cd9502">Table 6</a>.</p>
<a name="_Refid_f7baebb2-7ce6-4245-a8c8-949cd9502"></a><table width="100%">
<caption><span>Table 6. Selected Treatment-Emergent Adverse Reactions in All Pediatric Patients, in Patients with <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span> and Other <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> (C/IC), and in Hematopoietic Stem-Cell Recipients During Prophylaxis of <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </span></caption>
<col width="24%">
<col width="16%">
<col width="20%">
<col width="16%">
<col width="11%">
<col width="12%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="6" valign="top">Patient base: all randomized patients who received at least one dose of trial drug.<br><span class="Sup">¥</span> MedDRA v12.0<br><span class="Sup">†</span>Within a system organ class, patients may experience more than 1 adverse reaction.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><p class="First"><span class="Bold">System Organ Class</span><span class="Sup">¥</span><br><span class="Bold">(</span>Preferred Term<span class="Bold">) </span><span class="Sup">†</span></p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="bottom"><p class="First"><span class="Bold">All Micafungin-treated Patients</span><br><span class="Bold">n = 479</span><br><span class="Bold">n (%)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">C/IC</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="bottom"><p class="First"><span class="Bold">Prophylaxis</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold"> Mycamine</span><br><span class="Bold">n = 56</span><br><span class="Bold">n (%)</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">AmBisome </span><br><span class="Bold">n = 56</span><br><span class="Bold">n (%)</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Mycamine</span><br><span class="Bold">n = 43</span><br><span class="Bold">n (%)</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Fluconazole</span><br><span class="Bold">n = 48</span><br><span class="Bold">n (%)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">285 (60)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">22 (40)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">18 (32)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">43 (100)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">45 (94)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">146 (31)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">10 (18)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 (14)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">28 (65)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">32 (67)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">106 (22)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4 (7)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">5 (9)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">22 (51)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">31 (65)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">91 (19)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4 (7)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4 (7)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">30 (70)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">25 (52)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">76 (16)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2 (4)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2 (4)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">15 (35)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">12 (25)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">29 (6)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 (19)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">6 (13)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">General disorders and administration site conditions</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">256 (53)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">14 (25)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">14 (25)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">41 (95)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">46 (96)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">103 (22)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">5 (9)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">9 (16)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">26 (61)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">31 (65)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="438661" conceptname="Complication of infusion">Infusion related reaction</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">24 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">7 (16)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Skin and subcutaneous tissue disorders</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">197 (41)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">11 (20)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 (14)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">33 (77)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">38 (79)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">54 (11)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">14 (33)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">15 (31)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">55 (12)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">13 (30)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">13 (27)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">24 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 (19)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">194 (41)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">9 (16)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">13 (23)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">30 (70)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">33 (69)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">45 (9)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4 (9)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 (17)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Blood and lymphatic system disorders</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">161 (34)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">17 (30)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">13 (23)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">40 (93)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">44 (92)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">70 (15)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">5 (9)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">31 (72)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">37 (77)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">61 (13)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4 (7)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">33 (77)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">34 (71)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">63 (13)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">10 (18)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">6 (11)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">22 (51)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">24 (50)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">23 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">7 (16)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">7 (15)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Investigations</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">191 (40)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">12 (21)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 (14)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">24 (56)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">25 (52)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">45 (10)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">7 (16)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1 (2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First">Urine output decreased</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">18 (4)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">10 (23)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 (17)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">97 (20)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">7 (13)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">10 (23)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">17 (35)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">47 (10)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2 (4)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">7 (16)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">12 (25)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Renal and urinary disorders</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">78 (16)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4 (7)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4 (7)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">16 (37)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">15 (31)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">18 (4)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">10 (23)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">7 (15)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="Bold">Psychiatric disorders</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">80 (17)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">20 (47)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">9 (19)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="bottom"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">35 (7)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">10 (23)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3 (6)</p></td>
</tr>
</tbody>
</table>
<p> Other clinically significant adverse reactions reported at less than 15% in pediatric clinical trials are listed below:</p>
<dl>
<dt>•</dt>
<dd>
<span class="Italics">Hepatobiliary disorders</span>: <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span></dd>
<dt>•</dt>
<dd>
<span class="Italics">Investigations: </span><span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function tests abnormal</span></dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f348a89-5ed5-4c5b-82c1-2edf69e3f842"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Postmarketing Adverse Reactions</h2>
<p class="First">The following adverse reactions have been identified during the post-approval use of micafungin sodium for injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.</p>
<dl>
<dt>•</dt>
<dd>
<span class="Italics">Blood and lymphatic system disorders</span>: <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span></dd>
<dt>•</dt>
<dd>
<span class="Italics">Hepatobiliary disorders: </span> hepatic disorder</dd>
<dt>•</dt>
<dd>
<span class="Italics">Renal and urinary disorders</span>: <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span></dd>
<dt>•</dt>
<dd>
<span class="Italics">Skin and subcutaneous tissue disorders</span>: <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span></dd>
<dt>•</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span>: <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span></dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_8092a9e4-3fdc-4b0d-8201-8b6754a0acba"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">A total of 14 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between Mycamine and amphotericin B, mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, itraconazole, voriconazole, ritonavir, and rifampin. In these studies, no interaction that altered the pharmacokinetics of Mycamine was observed. </p>
<p>There was no effect of a single dose or multiple doses of Mycamine on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, fluconazole, and voriconazole pharmacokinetics. </p>
<p>Sirolimus AUC was increased by 21% with no effect on C<span class="Sub">max</span> in the presence of steady-state Mycamine compared with sirolimus alone. Nifedipine AUC and C<span class="Sub">max</span> were increased by 18% and 42%, respectively, in the presence of steady-state Mycamine compared with nifedipine alone. Itraconazole AUC and C<span class="Sub">max</span> were increased by 22% and 11%, respectively. </p>
<p>Patients receiving sirolimus, nifedipine or itraconazole in combination with Mycamine should be monitored for sirolimus, nifedipine or itraconazole toxicity and the sirolimus, nifedipine or itraconazole dosage should be reduced if necessary <span class="Italics">[see <a href="#i4i_clinical_pharmacology_id_95227aad-3a1d-4117-8e4d-a0dc35fff41c">Clinical Pharmacology</a> (<a href="#i4i_clinical_pharmacology_id_95227aad-3a1d-4117-8e4d-a0dc35fff41c">12</a>)]</span>.</p>
<p>Micafungin is neither a substrate nor an inhibitor of P-glycoprotein and, therefore, would not be expected to alter P-glycoprotein-mediated drug transport activity. </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_ef7ab1e9-4e17-418f-8b10-fbb83fa0e668"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_dadbdba4-b44c-460f-8bff-8b2f16d3cbce"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category C. There are no adequate and well-controlled studies of Mycamine in pregnant women. Animal reproduction studies in rabbits showed visceral abnormalities and increased abortion at 4 times the recommended human dose. However, animal studies are not always predictive of human response. Mycamine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p>When pregnant rabbits were given 4 times the recommended human dose, there were increased abortion and visceral abnormalities including abnormal lobation of the lung, levocardia, retrocaval ureter, anomalous right subclavian artery, and dilatation of the ureter <span class="Italics">[see <a href="#i4i_animal_pharmacology_id_ccfc4149-e775-496e-b3e6-c60b54cbef4d">Nonclinical Toxicology</a> (<a href="#i4i_animal_pharmacology_id_ccfc4149-e775-496e-b3e6-c60b54cbef4d">13.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_cc80daf1-46a1-493b-93c3-3c8793634103"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether micafungin is excreted in human milk. Caution should be exercised when Mycamine is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_8a7875b6-07a6-4570-8f82-13f472e6c516"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients younger than 4 months of age have not been established. </p>
<p>Safety and effectiveness of Mycamine in pediatric patients 4 months of age and older have been demonstrated based on the evidence from adequate and well-controlled studies in adult and pediatric patients and additional pediatric pharmacokinetic and safety data.  Two randomized, double-blind, active control studies investigated the safety and efficacy of Mycamine in both adult and pediatric patients: one for the treatment of <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">invasive candidiasis</span> and <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> and the other for prophylaxis of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in patients undergoing HSCT <span class="Italics">[see <a href="#i4i_dosage_admin_id_e0bf5887-433d-444c-878c-e24214e01145">Dosage and Administration</a> (<a href="#i4i_dosage_admin_id_e0bf5887-433d-444c-878c-e24214e01145">2</a>), <a href="#i4i_adverse_effects_id_8383637c-52d9-4ecc-acf8-86cf86fabb1b">Adverse Reactions</a> (<a href="#i4i_section_id_ea1b22ba-8f62-40f2-86c6-a88dd696c4c1">6.3</a>), <a href="#i4i_clinical_pharmacology_id_95227aad-3a1d-4117-8e4d-a0dc35fff41c">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_feb9060d-ee23-488e-b8e7-6505f383c69a">12.3</a>), <a href="#i4i_clinical_studies_id_71ef6c36-4269-45a3-be76-975f330b8599">Clinical Studies</a> (<a href="#i4i_clinical_studies_id_71ef6c36-4269-45a3-be76-975f330b8599">14</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_7daf8326-ba7e-465f-82e0-6fe2a164c1ff"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">A total of 418 subjects in clinical studies of Mycamine were 65 years of age and older, and 124 subjects were 75 years of age and older. No overall differences in safety and effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>The exposure and disposition of a 50 mg Mycamine dose administered as a single 1-hour infusion to 10 healthy subjects aged 66-78 years were not significantly different from those in 10 healthy subjects aged 20-24 years. No dose adjustment is necessary for the elderly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4a204fdd-db15-4b10-b671-2bac1389e3bf"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Mycamine does not require dose adjustment in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Supplementary dosing should not be required following hemodialysis <span class="Italics">[see <a href="#i4i_clinical_pharmacology_id_95227aad-3a1d-4117-8e4d-a0dc35fff41c">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_feb9060d-ee23-488e-b8e7-6505f383c69a">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a8163223-f364-41c4-a808-a30771693673"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Dose adjustment of Mycamine is not required in patients with mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#i4i_clinical_pharmacology_id_95227aad-3a1d-4117-8e4d-a0dc35fff41c">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_feb9060d-ee23-488e-b8e7-6505f383c69a">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_86a3d672-312c-4963-ad61-8df5b92067c4"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Race and Gender</h2>
<p class="First">No dose adjustment of Mycamine is required based on gender or race. After 14 daily doses of 150 mg to healthy subjects, micafungin AUC in women was greater by approximately 23% compared with men, due to smaller body weight. No notable differences among white, black, and Hispanic subjects were seen. The micafungin AUC was greater by 19% in Japanese subjects compared to blacks, due to smaller body weight. </p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_cb432eb3-d842-41c4-bdfd-7727449e68ab"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">There has been no evidence of either psychological or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> or withdrawal or rebound effects with Mycamine. </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_3b55d1cb-78c1-4ed7-ba7b-e99b7052d226"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Mycamine is highly protein bound and, therefore, is not dialyzable. No cases of Mycamine overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients, up to 6 mg/kg in pediatric patients 4 months of age and older, and up to 10 mg/kg in pediatric patients less than 4 months of age have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose of Mycamine is 125 mg/kg in rats, equivalent to 8 times the recommended highest adult clinical dose (150 mg) and approximately 7 times the highest pediatric clinical dose (3 mg/kg), based on body surface area comparisons.  </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_b68dcb9d-f9ca-4a9e-909e-bf78b6ffb4b9"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Mycamine is a sterile, lyophilized product for intravenous (IV) infusion that contains micafungin sodium. Micafungin sodium is a semisynthetic lipopeptide (echinocandin) synthesized by a chemical modification of a fermentation product of <span class="Italics">Coleophoma empetri</span> F-11899. Micafungin inhibits the synthesis of 1, 3-beta-D-glucan, an integral component of the fungal cell wall. </p>
<p>Each single-use vial contains 50 mg or 100 mg micafungin sodium, 200 mg lactose, with citric acid and/or sodium hydroxide (used for pH adjustment). Mycamine must be diluted with 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP <span class="Italics">[see <a href="#i4i_dosage_admin_id_e0bf5887-433d-444c-878c-e24214e01145">Dosage and Administration</a> (<a href="#i4i_dosage_admin_id_e0bf5887-433d-444c-878c-e24214e01145">2</a>)]</span>. Following reconstitution with 0.9% Sodium Chloride Injection, USP, the resulting pH of the solution is between 5-7. </p>
<p>Micafungin sodium is chemically designated as: </p>
<p>Pneumocandin A0,1-[(4<span class="Italics">R</span>,5<span class="Italics">R</span>)-4,5-dihydroxy-<span class="Italics">N</span><span class="Sup">2</span>-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4<span class="Italics">S</span>)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]-, monosodium salt. </p>
<p>The chemical structure of micafungin sodium is:</p>
<div class="Figure">
<a name="id1608"></a><img alt="Micafungin sodium structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc234dd7-5221-4a68-b153-aa0393c75bbf&amp;name=image-01.jpg">
</div>
<p>The empirical/molecular formula is C<span class="Sub">56</span>H<span class="Sub">70</span>N<span class="Sub">9</span>NaO<span class="Sub">23</span>S and the formula weight is 1292.26.</p>
<p>Micafungin sodium is a light-sensitive, hygroscopic white powder that is freely soluble in water, isotonic sodium chloride solution, N,N-dimethylformamide and dimethylsulfoxide, slightly soluble in methyl alcohol, and practically insoluble in acetonitrile, ethyl alcohol (95%), acetone, diethyl ether and n-hexane.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_95227aad-3a1d-4117-8e4d-a0dc35fff41c"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_ac6e7dd8-9e29-4b15-8659-30ba2704e9ca"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Micafungin is a member of the echinocandin class of antifungal agents <span class="Italics">[see <a href="#i4i_section_id_914a92f5-5b2a-44d1-9dab-7d746432ef7b">Clinical Pharmacology</a> (<a href="#i4i_section_id_914a92f5-5b2a-44d1-9dab-7d746432ef7b">12.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_feb9060d-ee23-488e-b8e7-6505f383c69a"></a><a name="section-12.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics"><span class="Underline">Adults</span></span></span></p>
<p>The pharmacokinetics of micafungin were determined in healthy subjects, hematopoietic stem cell transplant recipients, and patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span> up to a maximum daily dose of 8 mg/kg body weight.</p>
<p>The relationship of area under the concentration-time curve (AUC) to micafungin dose was linear over the daily dose range of 50 mg to 150 mg and 3 mg/kg to 8 mg/kg body weight. </p>
<p>Steady-state pharmacokinetic parameters in relevant patient populations after repeated daily administration are presented in <a href="#_Refid_2a219549-1219-443e-8bfc-b8298932a">Table 7</a>.</p>
<a name="_Refid_2a219549-1219-443e-8bfc-b8298932a"></a><table width="100%">
<caption><span>Table 7. Pharmacokinetic Parameters of Micafungin in Adult Patients</span></caption>
<col width="21%">
<col width="5%">
<col width="11%">
<col width="16%">
<col width="16%">
<col width="16%">
<col width="16%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>AUC<span class="Sub">0-infinity</span> is presented for day 1; AUC<span class="Sub">0-24</span> is presented for steady state.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span> or other <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">§</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span></dd>
<dt><a name="footnote-8" href="#footnote-reference-8">¶</a></dt>
<dd>hematopoietic stem cell transplant</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="middle"><p class="First"><span class="Bold">Population</span></p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="middle"><p class="First"><span class="Bold">n</span></p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="middle"><p class="First"><span class="Bold">Dose (mg)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="middle">
<p class="First"><span class="Bold">Pharmacokinetic Parameters</span></p>
<p><span class="Bold">(Mean ± Standard Deviation)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">C<span class="Sub">max</span></span></p>
<p><span class="Bold">(mcg/mL)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">AUC<span class="Sub">0-24</span></span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p>
<p><span class="Bold">(mcg·h/mL)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">t<span class="Sub">½</span></span></p>
<p><span class="Bold">(h)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First"><span class="Bold">Cl</span></p>
<p><span class="Bold">(mL/min/kg)</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule" valign="middle">
<p class="First">Patients with IC<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a></p>
<p>[Day 1]</p>
</td>
<td class="Rrule" align="center" valign="middle"><p class="First">20</p></td>
<td class="Rrule" align="center" valign="middle"><p class="First">100</p></td>
<td class="Rrule" align="center" valign="middle"><p class="First">5.7±2.2</p></td>
<td class="Rrule" align="center" valign="middle"><p class="First">83±51</p></td>
<td class="Rrule" align="center" valign="middle"><p class="First">14.5±7.0</p></td>
<td class="Rrule" align="center" valign="middle"><p class="First">0.359±0.179</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">[Steady State]</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">20</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">100</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">10.1±4.4</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">97±29</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">13.4±2.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.298±0.115</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="middle">
<p class="First">HIV<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a>- Positive</p>
<p>Patients with EC<a name="footnote-reference-7" href="#footnote-7" class="Sup">§</a> [Day 1]</p>
</td>
<td class="Rrule" align="center" valign="middle">
<p class="First">20</p>
<p>20</p>
<p>14</p>
</td>
<td class="Rrule" align="center" valign="middle">
<p class="First">50</p>
<p>100</p>
<p>150</p>
</td>
<td class="Rrule" align="center" valign="middle">
<p class="First">4.1±1.4</p>
<p>8.0±2.4</p>
<p>11.6±3.1</p>
</td>
<td class="Rrule" align="center" valign="middle">
<p class="First">36±9</p>
<p>108±31</p>
<p>151±45</p>
</td>
<td class="Rrule" align="center" valign="middle">
<p class="First">14.9±4.3</p>
<p>13.8±3.0</p>
<p>14.1±2.6</p>
</td>
<td class="Rrule" align="center" valign="middle">
<p class="First">0.321±0.098</p>
<p>0.327±0.093</p>
<p>0.340±0.092</p>
</td>
</tr>
<tr>
<td class="Lrule Rrule" valign="middle"><p class="First">   </p></td>
<td class="Rrule" valign="middle"></td>
<td class="Rrule" valign="middle"></td>
<td class="Rrule" valign="middle"></td>
<td class="Rrule" valign="middle"></td>
<td class="Rrule" valign="middle"></td>
<td class="Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">[Day 14 or 21]</p></td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">20</p>
<p>20</p>
<p>14</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">50</p>
<p>100</p>
<p>150</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">5.1±1.0</p>
<p>10.1±2.6</p>
<p>16.4±6.5</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">54±13</p>
<p>115±25</p>
<p>167±40</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">15.6±2.8</p>
<p>16.9±4.4</p>
<p>15.2±2.2</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">0.300±0.063</p>
<p>0.301±0.086</p>
<p>0.297±0.081</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle">
<p class="First">HSCT<a name="footnote-reference-8" href="#footnote-8" class="Sup">¶</a></p>
<p>Recipients</p>
<p>[Day 7]</p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">8</p>
<p>10</p>
<p>8</p>
<p>8</p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Italics">per kg</span></p>
<p> </p>
<p>3</p>
<p>4</p>
<p>6</p>
<p>8</p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">21.1±2.84</p>
<p>29.2±6.2</p>
<p>38.4±6.9</p>
<p> 60.8±26.9</p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">234±34</p>
<p>339±72</p>
<p>479±157</p>
<p>663±212</p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">14.0±1.4</p>
<p>14.2±3.2</p>
<p>14.9±2.6</p>
<p>17.2±2.3</p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First">0.214±0.031</p>
<p>0.204±0.036</p>
<p>0.224±0.064</p>
<p>0.223±0.081</p>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics"><span class="Underline">Pediatric Patients 4 months of age and older</span></span></span></p>
<p>Micafungin pharmacokinetics in 229 pediatric patients 4 months through 16 years of age were characterized using population pharmacokinetics. Micafungin exposure was dose proportional across the dose and age range studied. </p>
<a name="_Refid_d6890767-cf84-41f6-99d4-7cf2eef18"></a><table width="100%">
<caption><span>Table 8. Summary (Mean +/- Standard Deviation) of Micafungin Pharmacokinetics in Pediatric Patients 4 Months of Age and older (Steady-State)</span></caption>
<col width="20%">
<col width="6%">
<col width="20%">
<col width="13%">
<col width="14%">
<col width="12%">
<col width="16%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="14" valign="top">
<span class="Sup">§</span> Or the equivalent if receiving the adult dose (50, 100, or 150 mg)<br><span class="Sup">†</span> Derived from simulations from the population PK model. <br><span class="Sup">‡</span> Derived from the population PK model </td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Body weight group</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Dose<span class="Sup">§</span></span><br><span class="Bold">mg/kg</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Cmax.ss<span class="Sup">†</span></span><br><span class="Bold">(mcg/mL)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">AUC.ss<span class="Sup">†</span></span><br><span class="Bold">(mcg·h /mL)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">t½<span class="Sup">‡</span></span><br><span class="Bold">(h)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">CL<span class="Sup">‡</span></span><br><span class="Bold">(mL/min/kg)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="3" valign="middle"><p class="First">30 kg or less</p></td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle"><p class="First">149</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">7.1 +/- 4.7 </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">55 +/- 16</p></td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle"><p class="First">12.5 +/- 4.6</p></td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle"><p class="First">0.328 +/- 0.091</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">14.2 +/- 9.3</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">109 +/- 31</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">3.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">21.3 +/- 14.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">164 +/- 47</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="3" valign="middle"><p class="First">Greater than 30 kg</p></td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle"><p class="First">80</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8.7 +/- 5.6</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">67 +/- 17</p></td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle"><p class="First">13.6 +/- 8.8</p></td>
<td class="Botrule Rrule" align="center" rowspan="3" valign="middle"><p class="First">0.241 +/- 0.061</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">17.5 +/- 11.2</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">134 +/- 33</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">2.5</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">23.0 +/- 14.5</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">176 +/- 42</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics"><span class="Underline">Special Populations</span></span></span></p>
<p><span class="Italics"><span class="Underline">Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>Mycamine does not require dose adjustment in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. A single 1-hour infusion of 100 mg Mycamine was administered to 9 adult subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30 mL/min) and to 9 age-, gender-, and weight-matched subjects with normal renal function (creatinine clearance greater than 80 mL/min). The maximum concentration (C<span class="Sub">max</span>) and AUC were not significantly altered by severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
<p>Since micafungin is highly protein bound, it is not dialyzable. Supplementary dosing should not be required following hemodialysis.</p>
<p><span class="Italics"><span class="Underline">Adult Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<dl>
<dt>•</dt>
<dd>A single 1-hour infusion of 100 mg Mycamine was administered to 8 adult subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 7-9) and 8 age-, gender-, and weight-matched subjects with normal hepatic function. The C<span class="Sub">max</span> and AUC values of micafungin were lower by approximately 22% in subjects with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to normal subjects. This difference in micafungin exposure does not require dose adjustment of Mycamine in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </dd>
<dt>•</dt>
<dd>A single 1-hour infusion of 100 mg Mycamine was administered to 8 adult subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh score 10-12) and 8 age-, gender-, ethnic- and weight-matched subjects with normal hepatic function. The mean C<span class="Sub">max</span> and AUC values of micafungin were lower by approximately 30% in subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to normal subjects. The mean C<span class="Sub">max</span> and AUC values of M-5 metabolite were approximately 2.3-fold higher in subjects with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared to normal subjects; however, this exposure (parent and metabolite) was comparable to that in patients with systemic <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Therefore, no Mycamine dose adjustment is necessary in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </dd>
</dl>
<p><span class="Italics"><span class="Underline">Distribution</span></span></p>
<p>The mean ± standard deviation volume of distribution of micafungin at terminal phase was 0.39 ± 0.11 L/kg body weight when determined in adult patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span> at the dose range of 50 mg to 150 mg.</p>
<p>Micafungin is highly (greater than 99%) protein bound <span class="Italics">in vitro</span>, independent of plasma concentrations over the range of 10 to 100 mcg/mL. The primary binding protein is albumin; however, micafungin, at therapeutically relevant concentrations, does not competitively displace bilirubin binding to albumin. Micafungin also binds to a lesser extent to α1-acid-glycoprotein.</p>
<p><span class="Italics"><span class="Underline">Metabolism</span></span></p>
<p>Micafungin is metabolized to M-1 (catechol form) by arylsulfatase, with further metabolism to M-2 (methoxy form) by catechol-<span class="Italics">O-</span>methyltransferase. M-5 is formed by hydroxylation at the side chain (ω-1 position) of micafungin catalyzed by cytochrome P450 (CYP) isozymes. Even though micafungin is a substrate for and a weak inhibitor of CYP3A <span class="Italics">in vitro</span>, hydroxylation by CYP3A is not a major pathway for micafungin metabolism <span class="Italics">in vivo</span>. Micafungin is neither a P-glycoprotein substrate nor inhibitor <span class="Italics">in vitro</span>. </p>
<p>In four healthy volunteer studies, the ratio of metabolite to parent exposure (AUC) at a dose of 150 mg/day was 6% for M-1, 1% for M-2, and 6% for M-5. In patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>, the ratio of metabolite to parent exposure (AUC) at a dose of 150 mg/day was 11% for M-1, 2% for M-2, and 12% for M-5.</p>
<p><span class="Italics"><span class="Underline">Excretion</span></span></p>
<p>The excretion of radioactivity following a single intravenous dose of <span class="Sup">14</span>C-micafungin sodium for injection (25 mg) was evaluated in healthy volunteers. At 28 days after administration, mean urinary and fecal recovery of total radioactivity accounted for 82.5% (76.4% to 87.9%) of the administered dose. Fecal excretion is the major route of elimination (total radioactivity at 28 days was 71% of the administered dose). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_914a92f5-5b2a-44d1-9dab-7d746432ef7b"></a><a name="section-12.3"></a><p></p>
<h2>12.4 Microbiology </h2>
<p class="First"><span class="Italics"><span class="Underline">Mechanism of Action</span></span></p>
<p>Micafungin inhibits the synthesis of 1, 3-beta-D-glucan, an essential component of fungal cell walls, which is not present in mammalian cells.</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></span></span></p>
<p>There have been reports of clinical failures in patients receiving Mycamine therapy due to the development of <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>. Some of these reports have identified specific mutations in the <span class="Italics">FKS </span>protein component of the glucan synthase enzyme that are associated with higher MICs and breakthrough <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Italics"><span class="Underline">Activity In Vitro and In Clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span></p>
<p>Micafungin has been shown to be active against most isolates of the following <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species, both <span class="Bold"><span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span>:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans </span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> glabrata</span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> guilliermondii </span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> krusei </span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> parapsilosis</span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> tropicalis </span></p>
<p><span class="Italics"><span class="Underline">Susceptibility Testing Methods</span></span></p>
<p>The interpretive standards for micafungin against <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> species are applicable only to tests performed using Clinical Laboratory and Standards Institute (CLSI) microbroth dilution reference method M27-A3 for <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC; based on partial inhibition endpoint) and CLSI disk diffusion reference method M44-A2; both MIC and zone diameter results are read at 24 hours.</p>
<p>When available, the clinical microbiology laboratory should provide the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of pathogens. These reports should aid the physician in selecting an antifungal drug product for treatment. The techniques for Broth Microdilution and Disk Diffusion are described below.</p>
<p><span class="Italics">Broth Microdilution Technique</span></p>
<p>Quantitative methods are used to determine antifungal MICs. These MICs provide estimates of the susceptibility of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span>species to antifungal agents. MICs should be determined using a standardized CLSI procedure<span class="Sup">1,2</span>. Standardized procedures are based on a microdilution method (broth) with standardized inoculum concentrations and standardized concentrations of micafungin powder. The MIC values should be interpreted according to the criteria provided in <a href="#_Refid_174b2e52-4df5-4ee5-bb08-2c5a41a55">Table 9</a>.</p>
<p><span class="Italics">Disk Diffusion Technique</span></p>
<p>Qualitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span>species to antifungal agents. The CLSI procedure<span class="Sup">3</span> uses standardized inoculum concentrations and paper disks impregnated with 10 mcg of micafungin to test the susceptibility of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span>species to micafungin at 24 hours. Disk diffusion interpretive criteria are provided in <a href="#_Refid_174b2e52-4df5-4ee5-bb08-2c5a41a55">Table 9</a>.</p>
<a name="_Refid_174b2e52-4df5-4ee5-bb08-2c5a41a55"></a><table width="100%">
<caption><span>Table 9. Susceptibility Interpretive Criteria for Micafungin</span></caption>
<col width="17%">
<col width="16%">
<col width="14%">
<col width="13%">
<col width="13%">
<col width="14%">
<col width="13%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="7" valign="top">MIC: <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span><br><span class="Sup">†</span> Disk diffusion zone diameters have not been established for this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>/antifungal agent combination.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="bottom"><p class="First"><span class="Bold">Pathogen</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="bottom"><p class="First"><span class="Bold">Broth Microdilution MIC (mcg/mL) </span><br><span class="Bold">at 24 hours</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3" valign="bottom">
<p class="First"><span class="Bold">Disk Diffusion at 24 hours</span></p>
<p><span class="Bold">(Zone diameters in mm)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Susceptible</span></p>
<p><span class="Bold">(S)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Intermediate (I)</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Resistant</span></p>
<p><span class="Bold">(R)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Susceptible</span></p>
<p><span class="Bold">(S)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First"><span class="Bold">Intermediate (I)</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom">
<p class="First"><span class="Bold">Resistant</span></p>
<p><span class="Bold">(R)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≤ 0.25</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.5</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥ 1</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥ 22</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">20-21</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≤ 19</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> tropicalis</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≤ 0.25</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.5</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥ 1</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥ 22</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">20-21</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≤ 19</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> krusei</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≤ 0.25</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.5</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥ 1</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥ 22</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">20-21</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≤ 19</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> parapsilosis</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≤ 2</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥ 8</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥ 16</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">14-15</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≤ 13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> guilliermondii</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≤ 2</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥ 8</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥ 16</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">14-15</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≤ 13</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> glabrata</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≤ 0.06</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.12</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">≥ 0.25</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">Not Applicable<span class="Sup">†</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">Not Applicable<span class="Sup">†</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">Not Applicable<span class="Sup">†</span></p></td>
</tr>
</tbody>
</table>
<p>A report of “Susceptible? indicates that the isolate is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable.</p>
<p>The “Intermediate? category implies that an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> due to the isolate may be appropriately treated in body sites where the drug is physiologically concentrated or when a high dosage of drug is used. The “Resistant? category implies that the isolates are not inhibited by the concentrations of the drug usually achievable with normal dosage schedules and clinical efficacy of the drug against the pathogen has not been reliably shown in treatment studies.</p>
<p><span class="Italics"><span class="Underline">Quality Control</span></span></p>
<p>Standardized susceptibility test procedures require the use of quality control organisms to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the technique of the individual performing the test<span class="Sup">1, 2, 3</span>. Standard micafungin powder and 10 mcg disks should provide the following range of values noted in <a href="#_Refid_10db41db-be42-47b4-9f4c-6072685e2">Table 10</a>.</p>
<a name="_Refid_10db41db-be42-47b4-9f4c-6072685e2"></a><table width="100%">
<caption><span>Table 10. Acceptable Quality Control Ranges for Micafungin to be Used in Validation of Susceptibility Test Results</span></caption>
<col width="29%">
<col width="41%">
<col width="29%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="10" valign="top">MIC: <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span><br><span class="Sup">†</span> ATCC is a registered trademark of the American Type Culture Collection.<br><span class="Sup">‡</span> Quality control ranges have not been established for this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>/antifungal agent combination.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"><p class="First"><span class="Bold">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span></span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Broth microdilution (MIC in mcg/mL) at 24- hour</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Disk Diffusion</span></p>
<p><span class="Bold">(Zone diameter in mm) at 24-hour</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> parapsilosis </span>ATCC<span class="Sup">†</span> 22019</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.5 – 2.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">14 – 23</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> krusei </span>ATCC 6258</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.12 – 0.5</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">23 – 29</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> tropicalis</span> ATCC 750</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">Not Applicable<span class="Sup">‡</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">24 – 30</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans </span>ATCC 90028</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">Not Applicable<span class="Sup">‡</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">24 – 31</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_7fdae90d-62b7-41b8-9216-a836121579ee"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_98ecc559-376d-42cc-8466-dbf304054794"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Hepatic carcinomas and <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> were observed in a 6-month intravenous toxicology study with an 18-month recovery period of micafungin sodium in rats designed to assess the reversibility of hepatocellular lesions. </p>
<p>Rats administered micafungin sodium for 3 months at 32 mg/kg/day (corresponding to 8 times the highest recommended human dose [150 mg/day], based on AUC comparisons), exhibited colored patches/zones, multinucleated hepatocytes and altered hepatocellular foci after 1 or 3 month recovery periods, and <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> were observed after a 21-month recovery period. Rats administered micafungin sodium at the same dose for 6 months exhibited <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> after a 12-month recovery period; after an 18-month recovery period, an increased incidence of <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> was observed, and additionally, carcinomas were detected. A lower dose of micafungin sodium (equivalent to 5 times the human AUC) in the 6-month rat study resulted in a lower incidence of <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas following 18 months recovery. The duration of micafungin dosing in these rat studies (3 or 6 months) exceeds the usual duration of Mycamine dosing in patients, which is typically less than 1 month for treatment of <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>, but dosing may exceed 1 month for <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> prophylaxis. </p>
<p>Although the increase in carcinomas in the 6-month rat study did not reach statistical significance, the persistence of altered hepatocellular foci subsequent to Mycamine dosing, and the presence of <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas in the recovery periods suggest a causal relationship between micafungin sodium, altered hepatocellular foci, and <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">hepatic neoplasms</span>. Whole-life carcinogenicity studies of Mycamine in animals have not been conducted, and it is not known whether the <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">hepatic neoplasms</span> observed in treated rats also occur in other species, or if there is a dose threshold for this effect.</p>
<p>Micafungin sodium was not mutagenic or clastogenic when evaluated in a standard battery of <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> tests (i.e., bacterial reversion - <span class="Italics">S. typhimurium, E. coli</span>; chromosomal aberration; intravenous mouse micronucleus).</p>
<p>Male rats treated intravenously with micafungin sodium for 9 weeks showed vacuolation of the epididymal ductal epithelial cells at or above 10 mg/kg (about 0.6 times the recommended clinical dose for <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>, based on body surface area comparisons). Higher doses (about twice the recommended clinical dose, based on body surface area comparisons) resulted in higher epididymis weights and reduced numbers of sperm cells. In a 39-week intravenous study in dogs, seminiferous tubular <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> and decreased sperm in the epididymis were observed at 10 and 32 mg/kg, doses equal to about 2 and 7 times the recommended clinical dose, based on body surface area comparisons. There was no impairment of fertility in animal studies with micafungin sodium. </p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_ccfc4149-e775-496e-b3e6-c60b54cbef4d"></a><a name="section-13.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">High doses of micafungin sodium (5 to 8 times the highest recommended human dose, based on AUC comparisons) have been associated with irreversible changes to the liver when administered for 3 or 6 months, and these changes may be indicative of pre-malignant processes <span class="Italics">[see <a href="#i4i_carcinogenesis_mutagenesis_fertility_id_98ecc559-376d-42cc-8466-dbf304054794">Nonclinical Toxicology</a> (<a href="#i4i_carcinogenesis_mutagenesis_fertility_id_98ecc559-376d-42cc-8466-dbf304054794">13.1</a>)]</span>. </p>
<p><span class="Italics"><span class="Underline">Reproductive Toxicology Studies</span></span></p>
<p>Micafungin sodium administration to pregnant rabbits (intravenous dosing on days 6 to 18 of gestation) resulted in visceral abnormalities and abortion at 32 mg/kg, a dose equivalent to about four times the recommended dose based on body surface area comparisons. Visceral abnormalities included abnormal lobation of the lung, levocardia, retrocaval ureter, anomalous right subclavian artery, and dilatation of the ureter.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_71ef6c36-4269-45a3-be76-975f330b8599"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c1c6d5d8-ba62-4a0b-b50c-2bcf0f716923"></a><a name="section-14.1"></a><p></p>
<h2>14.1 Adult Treatment of <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span> and Other <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Two dose levels of Mycamine were evaluated in a randomized, double-blind study to determine the efficacy and safety versus caspofungin in patients with <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">invasive candidiasis</span> and <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span>.  Patients were randomized to receive once daily intravenous infusions (IV) of Mycamine, either 100 mg/day or 150 mg/day or caspofungin (70 mg loading dose followed by 50 mg maintenance dose).  Patients in both study arms were permitted to switch to oral fluconazole after at least 10 days of intravenous therapy, provided they were non-neutropenic, had improvement or resolution of clinical signs and symptoms, had a<span class="Italics"> <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> isolate which was susceptible to fluconazole, and had documentation of 2 negative cultures drawn at least 24 hours apart. Patients were stratified by APACHE II score (20 or less or greater than 20) and by geographic region.  Patients with <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> were excluded from this analysis. Outcome was assessed by overall treatment success based on clinical (complete resolution or improvement in attributable signs and symptoms and radiographic abnormalities of the <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and no additional antifungal therapy) and mycological (eradication or presumed eradication) response at the end of IV therapy.  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> that occurred during IV study drug therapy were treated as failures. </p>
<p>In this study, 111/578 (19.2%) of the patients had baseline APACHE II scores of greater than 20, and 50/578 (8.7%) were neutropenic at baseline (absolute neutrophil count less than 500 cells/mm<span class="Sup">3</span>). Outcome, relapse and mortality data are shown for the recommended dose of Mycamine (100 mg/day) and caspofungin in <a href="#_Refid_e01c7d8e-4a04-4d22-8691-ac3f9a9a5">Table 11</a>. </p>
<a name="_Refid_e01c7d8e-4a04-4d22-8691-ac3f9a9a5"></a><table width="100%">
<caption><span>Table 11. Efficacy Analysis: Treatment Success in Patients in Study 03-0-192 with <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span> and other <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></caption>
<col width="48%">
<col width="24%">
<col width="28%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>70 mg loading dose on day 1 followed by 50 mg/day thereafter (caspofungin)</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>All patients who received at least one dose of study medication and had documented <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">invasive candidiasis</span> or <span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">candidemia</span>. Patients with <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">endocarditis</span> were excluded from the analyses.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">‡</a></dt>
<dd>A patient may have had greater than 1 organ of dissemination</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">§</a></dt>
<dd>A patient may have had greater than 1 baseline <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> species</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">¶</a></dt>
<dd>All patients who had a culture confirmed relapse or required systemic antifungal therapy in the post treatment period for a suspected or proven <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Also includes patients who died or were not assessed in follow-up.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Mycamine 100 mg/day</span></p>
<p><span class="Bold">n (%)</span></p>
<p><span class="Bold">% treatment difference</span></p>
<p><span class="Bold">(95%CI)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Caspofungin 70/50 mg/day</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></p>
<p><span class="Bold">n (%)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Treatment Success at End of IV Therapy</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a><br>   <br>   </p></td>
<td class="Botrule Rrule" align="center">
<p class="First">135/191 (70.7)</p>
<p>7.4</p>
<p>(-2.0, 16.3)</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">119/188 (63.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Success in Patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> at Baseline</span></p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First">14/22 (63.6)</p></td>
<td class="Botrule Rrule" align="center" valign="bottom"><p class="First">5/11 (45.5)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Success by Site of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></p></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="438077" conceptname="Invasive candidiasis">Candidemia</span></span></p></td>
<td class="Rrule" align="center"><p class="First">116/163 (71.2)</p></td>
<td class="Rrule" align="center"><p class="First">103/161 (64)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscess</span></span></p></td>
<td class="Rrule" align="center"><p class="First">4/5 (80)</p></td>
<td class="Rrule" align="center"><p class="First">5/9 (55.6)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Acute Disseminated</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">‡</a></p></td>
<td class="Rrule" align="center"><p class="First">6/13 (46.2)</p></td>
<td class="Rrule" align="center"><p class="First">5/9 (55.6)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">Endophthalmitis</span></p></td>
<td class="Rrule" align="center"><p class="First">1/3</p></td>
<td class="Rrule" align="center"><p class="First">1/1</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     <span class="product-label-link" type="condition" conceptid="434033" conceptname="Chorioretinitis">Chorioretinitis</span></p></td>
<td class="Rrule" align="center"><p class="First">0/3</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     Skin</p></td>
<td class="Rrule" align="center"><p class="First">1/1</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     Kidney</p></td>
<td class="Rrule" align="center"><p class="First">2/2</p></td>
<td class="Rrule" align="center"><p class="First">1/1 </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     Pancreas</p></td>
<td class="Rrule" align="center"><p class="First">1/1</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     Peritoneum</p></td>
<td class="Rrule" align="center"><p class="First">1/1</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     Lung/Skin</p></td>
<td class="Rrule" align="center"><p class="First">0/1</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     Lung/Spleen</p></td>
<td class="Rrule" align="center"><p class="First">0/1</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     Liver</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
<td class="Rrule" align="center"><p class="First">0/2</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     Intraabdominal <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span></p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
<td class="Rrule" align="center"><p class="First">3/5 </p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Chronic Disseminated</span></p></td>
<td class="Rrule" align="center"><p class="First">0/1</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">Peritonitis</span></span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4/6 (66.7)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2/5 (40)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Success by Organism</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">§</a></p></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Italics">     C. albicans</span></p></td>
<td class="Rrule" align="center"><p class="First">57/81 (70.4)</p></td>
<td class="Rrule" align="center"><p class="First">45/73 (61.6)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Italics">     C. glabrata</span></p></td>
<td class="Rrule" align="center"><p class="First">16/23 (69.6)</p></td>
<td class="Rrule" align="center"><p class="First">19/31 (61.3)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Italics">     C. tropicalis</span></p></td>
<td class="Rrule" align="center"><p class="First">17/27 (63)</p></td>
<td class="Rrule" align="center"><p class="First">22/29 (75.9)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Italics">     C. parapsilosis</span></p></td>
<td class="Rrule" align="center"><p class="First">21/28 (75)</p></td>
<td class="Rrule" align="center"><p class="First">22/39 (56.4)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Italics">     C. krusei</span></p></td>
<td class="Rrule" align="center"><p class="First">5/8 (62.5)</p></td>
<td class="Rrule" align="center"><p class="First">2/3 (66.7)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Italics">     C. guilliermondii</span></p></td>
<td class="Rrule" align="center"><p class="First">1/2</p></td>
<td class="Rrule" align="center"><p class="First">0/1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Italics">     C. lusitaniae</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2/3 (66.7)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2/2</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Relapse through 6 Weeks</span><a name="footnote-reference-13" href="#footnote-13" class="Sup">¶</a></p></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Overall</p></td>
<td class="Rrule" align="center"><p class="First">49/135 (36.3)</p></td>
<td class="Rrule" align="center"><p class="First">44/119 (37)</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     Culture confirmed relapse</p></td>
<td class="Rrule" align="center"><p class="First">5</p></td>
<td class="Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     Required systemic antifungal therapy</p></td>
<td class="Rrule" align="center"><p class="First">11</p></td>
<td class="Rrule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">     Died during follow-up</p></td>
<td class="Rrule" align="center"><p class="First">17</p></td>
<td class="Rrule" align="center"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">     Not assessed</p></td>
<td class="Botrule Rrule" align="center"><p class="First">16</p></td>
<td class="Botrule Rrule" align="center"><p class="First">19</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First"><span class="Bold">Overall study mortality</span></p></td>
<td class="Rrule" align="center"><p class="First">58/200 (29)</p></td>
<td class="Rrule" align="center"><p class="First">51/193 (26.4)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">     Mortality during IV therapy</p></td>
<td class="Botrule Rrule" align="center"><p class="First">28/200 (14)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">27/193 (14)</p></td>
</tr>
</tbody>
</table>
<p>In two cases of ophthalmic involvement assessed as failures in the above table due to missing evaluation at the end of IV treatment with Mycamine, therapeutic success was documented during protocol-defined oral fluconazole therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_578d63b9-45e3-4f00-874c-0463c80da820"></a><a name="section-14.2"></a><p></p>
<h2>14.2 Adult Treatment of <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span></h2>
<p class="First">In two controlled trials involving 763 patients with <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>, 445 adults with endoscopically-proven <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> received Mycamine, and 318 received fluconazole for a median duration of 14 days (range 1-33 days).</p>
<p>Mycamine was evaluated in a randomized, double-blind study which compared Mycamine 150 mg/day (n = 260) to intravenous fluconazole 200 mg/day (n = 258) in adults with endoscopically-proven <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span>. Most patients in this study had <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>, with CD4 cell counts less than 100 cells/mm<span class="Sup">3</span>. Outcome was assessed by endoscopy and by clinical response at the end of treatment. Endoscopic cure was defined as endoscopic grade 0, based on a scale of 0-3. Clinical cure was defined as complete resolution in clinical symptoms of <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span> (<span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4147218" conceptname="Swallowing painful">odynophagia</span>, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">retrosternal pain</span>). Overall therapeutic cure was defined as both clinical and endoscopic cure. Mycological eradication was determined by culture, and by histological or cytological evaluation of esophageal biopsy or brushings obtained endoscopically at the end of treatment. As shown in <a href="#_Refid_1e792de3-8cd1-42ae-bba7-67f058d1b">Table 12</a>, endoscopic cure, clinical cure, overall therapeutic cure, and mycological eradication were comparable for patients in the Mycamine and fluconazole treatment groups.</p>
<a name="_Refid_1e792de3-8cd1-42ae-bba7-67f058d1b"></a><table width="100%">
<caption><span>Table 12. Endoscopic, Clinical, and Mycological Outcomes for <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span> at End-of-Treatment</span></caption>
<col width="26%">
<col width="18%">
<col width="18%">
<col width="20%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>Endoscopic and clinical outcome were measured in modified intent-to-treat population, including all randomized patients who received 1 or more doses of study treatment. Mycological outcome was determined in the per protocol (evaluable) population, including patients with confirmed <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span> who received at least 10 doses of study drug, and had no major protocol violations.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
<dd>Calculated as Mycamine – fluconazole</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Treatment Outcome</span><a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a><br>   </p></td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Mycamine</span></p>
<p><span class="Bold">150 mg/day</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Fluconazole</span></p>
<p><span class="Bold">200 mg/day</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">% Difference</span><a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a></p>
<p><span class="Bold">(95% CI)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Rrule" align="center"><p class="First">n = 260</p></td>
<td class="Botrule Rrule" align="center"><p class="First">n = 258</p></td>
<td class="Botrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Endoscopic Cure</p></td>
<td class="Botrule Rrule" align="center"><p class="First">228 (87.7%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">227 (88.0%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-0.3% (-5.9, +5.3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Clinical Cure</p></td>
<td class="Botrule Rrule" align="center"><p class="First">239 (91.9%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">237 (91.9%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.06% (-4.6, +4.8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Overall Therapeutic Cure</p></td>
<td class="Botrule Rrule" align="center"><p class="First">223 (85.8%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">220 (85.3%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0.5% (-5.6, +6.6)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">Mycological Eradication</p></td>
<td class="Botrule Rrule" align="center"><p class="First">141/189 (74.6%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">149/192 (77.6%)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">-3.0% (-11.6, +5.6)</p></td>
</tr>
</tbody>
</table>
<p>Most patients (96%) in this study had <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span> isolated at baseline. The efficacy of Mycamine was evaluated in less than 10 patients with <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span>species other than <span class="Italics">C. albicans</span>, most of which were isolated concurrently with <span class="Italics">C. albicans.</span></p>
<p>Relapse was assessed at 2 and 4 weeks post-treatment in patients with overall therapeutic cure at end of treatment. Relapse was defined as a recurrence of clinical symptoms or endoscopic lesions (endoscopic grade greater than 0). There was no statistically significant difference in relapse rates at either 2 weeks or through 4 weeks post-treatment for patients in the Mycamine and fluconazole treatment groups, as shown in <a href="#_Refid_6bf974e1-931e-47d1-8a16-e74a28039">Table 13</a>.</p>
<a name="_Refid_6bf974e1-931e-47d1-8a16-e74a28039"></a><table width="100%">
<caption><span>Table 13. Relapse of <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">Esophageal Candidiasis</span> at Week 2 and through Week 4 Post-Treatment in Patients with Overall Therapeutic Cure at the End of Treatment</span></caption>
<col width="39%">
<col width="14%">
<col width="14%">
<col width="18%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>Calculated as Mycamine – fluconazole; N = number of patients with overall therapeutic cure (both clinical and endoscopic cure at end-of-treatment);</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">†</a></dt>
<dd>Relapse included patients who died or were lost to follow-up, and those who received systemic anti-fungal therapy in the post-treatment period</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">Relapse</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Mycamine</span></p>
<p><span class="Bold">150 mg/day</span></p>
<p>n = 223</p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Fluconazole</span></p>
<p><span class="Bold">200 mg/day</span></p>
<p>n = 220</p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">% Difference</span><a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a></p>
<p><span class="Bold">(95% CI)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle">
<p class="First">Relapse<a name="footnote-reference-17" href="#footnote-17" class="Sup">†</a> at </p>
<p>Week 2</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">40 (17.9%)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">30 (13.6%)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4.3% (-2.5, 11.1)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Relapse<a href="#footnote-17" class="Sup">†</a> Through Week 4 (cumulative) </p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">73 (32.7%)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">62 (28.2%)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4.6% (-4.0, 13.1)</p></td>
</tr>
</tbody>
</table>
<p>In this study, 459 of 518 (88.6%) patients had <span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">oropharyngeal candidiasis</span> in addition to <span class="product-label-link" type="condition" conceptid="28974" conceptname="Candidiasis of the esophagus">esophageal candidiasis</span> at baseline. At the end of treatment 192/230 (83.5%) Mycamine treated patients and 188/229 (82.1%) of fluconazole treated patients experienced resolution of signs and symptoms of <span class="product-label-link" type="condition" conceptid="4080451" conceptname="Pharyngeal candidiasis">oropharyngeal candidiasis</span>. Of these, 32.3% in the Mycamine group, and 18.1% in the fluconazole group (treatment difference = 14.2%; 95% confidence interval [5.6, 22.8]) had symptomatic relapse at 2 weeks post-treatment. Relapse included patients who died or were lost to follow-up, and those who received systemic antifungal therapy during the post-treatment period. Cumulative relapse at 4 weeks post-treatment was 52.1% in the Mycamine group and 39.4% in the fluconazole group (treatment difference 12.7%, 95% confidence interval [2.8, 22.7]).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a22a0a17-c5d1-49d1-ae19-66542003a8d8"></a><a name="section-14.3"></a><p></p>
<h2>14.3 Prophylaxis of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Hematopoietic Stem Cell Transplant Recipients</h2>
<p class="First">In a randomized, double-blind study, Mycamine (50 mg IV once daily) was compared to fluconazole (400 mg IV once daily) in 882 [adult (791) and pediatric (91)] patients undergoing an autologous or syngeneic (46%) or allogeneic (54%) stem cell transplant. All pediatric patients, except 2 per group, received allogeneic transplants. The status of the patients’ underlying malignancy at the time of randomization was: 365 (41%) patients with active disease, 326 (37%) patients in remission, and 195 (22%) patients in relapse. The more common baseline underlying diseases in the 476 allogeneic transplant recipients were: <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic myelogenous leukemia</span> (22%), acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (21%), <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphocytic leukemia</span> (13%), and non-Hodgkin’s <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (13%). In the 404 autologous and syngeneic transplant recipients the more common baseline underlying diseases were: <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> (37.1%), non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (36.4%), and Hodgkin's disease (15.6%). During the study, 198 of 882 (22.4%) transplant recipients had proven graft-versus-host disease; and 475 of 882 (53.9%) recipients received immunosuppressive medications for treatment or prophylaxis of graft-versus-host disease. </p>
<p>Study drug was continued until the patient had neutrophil recovery to an absolute neutrophil count (ANC) of 500 cells/mm<span class="Sup">3</span> or greater or up to a maximum of 42 days after transplant. The average duration of drug administration was 18 days (range 1 to 51 days). Duration of therapy was slightly longer in the pediatric patients who received Mycamine (median duration 22 days) compared to the adult patients who received Mycamine (median duration 18 days).</p>
<p>Successful prophylaxis was defined as the absence of a proven, probable, or suspected systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> through the end of therapy (usually 18 days), and the absence of a proven or probable systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> through the end of the 4-week post-therapy period. A suspected systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> was diagnosed in patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (ANC less than 500 cells/mm<span class="Sup">3</span>); persistent or recurrent <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (while ANC less than 500 cells/mm<span class="Sup">3</span>) of no known etiology; and failure to respond to at least 96 hours of broad spectrum antibacterial therapy. A persistent <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> was defined as four consecutive days of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> greater than 38ºC. A recurrent <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> was defined as having at least one day with temperatures 38.5ºC or higher after having at least one prior temperature higher than 38ºC; or having two days of temperatures higher than 38ºC after having at least one prior temperature higher than 38ºC. Transplant recipients who died or were lost to follow-up during the study were considered failures of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy.</p>
<p>Successful prophylaxis was documented in 80.7% of adult and pediatric Mycamine recipients, and in 73.7% of adult and pediatric patients who received fluconazole (7.0% difference [95% CI = 1.5, 12.5]), as shown in <a href="#_Refid_2e4f6a2c-f11a-4395-936a-bf2c679af">Table 14</a>, along with other study endpoints. The use of systemic antifungal therapy post-treatment was 42% in both groups.</p>
<p>The number of proven breakthrough <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> was 4 in the Mycamine and 2 in the fluconazole group. </p>
<p>The efficacy of Mycamine against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by fungi other than <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> has not been established.</p>
<a name="_Refid_2e4f6a2c-f11a-4395-936a-bf2c679af"></a><table width="100%">
<caption><span>Table 14. Results from Clinical Study of Prophylaxis of <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> in Hematopoietic Stem Cell Transplant Recipients</span></caption>
<col width="56%">
<col width="14%">
<col width="14%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>Difference (Mycamine – fluconazole): +7.0% [95% CI=1.5, 12.5]</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">†</a></dt>
<dd>Through end-of-study (4 weeks post-therapy)</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">‡</a></dt>
<dd>Through end-of-therapy </dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Outcome of Prophylaxis<br>   <br>   </span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Mycamine</span></p>
<p><span class="Bold">50 mg/day</span></p>
<p><span class="Bold">(n = 425)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Fluconazole</span></p>
<p><span class="Bold">400 mg/day</span></p>
<p><span class="Bold">(n = 457)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Success <a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">343 (80.7%)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">337 (73.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Failure:</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">82 (19.3%)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">120 (26.3%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle">
<p class="First">   All Deaths <a name="footnote-reference-19" href="#footnote-19" class="Sup">†</a></p>
<p>   Proven/probable <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> prior to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">18 (4.2%)</p>
<p>1 (0.2%)</p>
</td>
<td class="Botrule Rrule" align="center" valign="middle">
<p class="First">26 (5.7%)</p>
<p>3 (0.7%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">   Proven/probable <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> (not resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) <a href="#footnote-19" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">6 (1.4%)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">8 (1.8%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">   Suspected <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> <a name="footnote-reference-20" href="#footnote-20" class="Sup">‡</a></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">53 (12.5%)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">83 (18.2%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">   Lost to follow-up</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">5 (1.2%)</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3 (0.7%)</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_c4dc98c2-410d-4e89-9a9f-ae5dc0ecc9c9"></a><a name="section-15"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First">1. Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts – Approved Standard – Third Edition. CLSI document M27-A3. Clinical and Laboratory Standards Institute, 950 West Valley Rd, Suite 2500, Wayne, PA 19087, USA, 2008.</p>
<p>2. Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Fourth Informational Supplement. CLSI document M27-S4. Clinical and Laboratory Standards Institute, 950 West Valley Rd, Suite 2500, Wayne, PA 19087, USA, 2012.</p>
<p>3. Clinical and Laboratory Standards Institute (CLSI). Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline - Second Edition. CLSI document M44-A2. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA 19087, USA, 2009.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_d7cb4073-dc24-4328-ba51-72c6ab39ab28"></a><a name="section-16"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Mycamine is available in:</p>
<dl>
<dt>•</dt>
<dd>cartons of 10 individually packaged 50 mg single-use vials, coated with a light protective film and sealed with a blue flip-off cap. (NDC 0469-3250-50).</dd>
<dt>•</dt>
<dd>cartons of 10 individually packaged 100 mg single-use vials, coated with a light protective film and sealed with a red flip-off cap. (NDC 0469-3211-99).</dd>
</dl>
<p><span class="Italics"><span class="Underline">Storage</span></span></p>
<p>Unopened vials of lyophilized material must be stored at room temperature, 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). <span class="Italics">[see USP Controlled Room Temperature.]</span></p>
<p>The reconstituted product may be stored in the original vial for up to 24 hours at room temperature, 25°C (77°F). </p>
<p>The diluted infusion should be protected from light and may be stored for up to 24 hours at room temperature, 25°C (77°F). </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_95d3a9be-9619-4b41-8430-60df6112f593"></a><a name="section-17"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be advised of the potential benefits and risks of Mycamine. Patients should be informed about the serious adverse effects of Mycamine including <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>), hematological effects (acute <span class="product-label-link" type="condition" conceptid="4049138" conceptname="Intravascular hemolysis">intravascular hemolysis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> and <span class="product-label-link" type="condition" conceptid="321414" conceptname="Hemoglobinuria">hemoglobinuria</span>), hepatic effects (<span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or worsening <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>) and renal effects (elevations in BUN and creatinine, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>). Patients should be instructed to inform their health care provider if they develop any unusual symptom, or if any known symptom persists or worsens. Patients should be instructed to inform their health care provider of any other medications they are currently taking with Mycamine, including over-the-counter medications.<br><br></p>
<p>Product of Japan</p>
<p>Manufactured by: <br><span class="Bold">Astellas Pharma Tech Co., Ltd. </span>Takaoka Plant<br>30 Toidesakae-machi, Takaoka city, Toyama 939-1118, Japan</p>
<p>Marketed by: <br><span class="Bold">Astellas Pharma US, Inc.</span><br>Northbrook, IL 60062 USA</p>
<p>14C012-MYC-SPL </p>
<p>Issued: April 2014</p>
<p>MYCAMINE is a registered trademark of Astellas Pharma, Inc., Tokyo, Japan.</p>
<p>NOVAPLUS is a registered trademark of Novation, LLC.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_c6798bc7-6799-456c-9509-3c3d65cd9fec"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL – 50 mg/vial</h1>
<div class="Figure">
<a name="id-589931982"></a><img alt="Mycamine (micafungin sodium) for injection 50 mg/vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc234dd7-5221-4a68-b153-aa0393c75bbf&amp;name=vial%20label.jpg">
</div>
<p class="First"><span class="Bold">  <br>50 mg Vial Label </span></p>
<p>NDC 0469-3250-50</p>
<p><span class="Bold">Mycamine<span class="Sup">®</span></span><br>micafungin sodium<br>for injection</p>
<p><span class="Bold">50 mg<br>per vial</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p>After reconstitution <span class="Bold">each mL contains 10 mg micafungin sodium.</span></p>
<p><span class="Bold">For Intravenous Infusion Only</span></p>
<p><span class="Bold">Single Use Vial.</span></p>
<p><span class="Bold">Discard unused portion.</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_43fc05a3-9f61-4d28-932a-a48a75d21859"></a><a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL – 100 mg/vial</h1>
<div class="Figure">
<a name="id-1227144168"></a><img alt="Mycamine (micafungin sodium) for injection 100 mg/vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc234dd7-5221-4a68-b153-aa0393c75bbf&amp;name=vial%20label-01.jpg">
</div>
<p class="First">  <br><span class="Bold">100 mg Vial Label </span></p>
<p>NDC 0469-3211-99</p>
<p><span class="Bold">Mycamine<span class="Sup">®</span></span><br>micafungin sodium<br>for injection</p>
<p><span class="Bold">100 mg<br>per vial</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p>After reconstitution <span class="Bold">each mL contains 20 mg micafungin sodium.</span></p>
<p><span class="Bold">For Intravenous Infusion Only</span></p>
<p><span class="Bold">Single Use Vial.</span></p>
<p><span class="Bold">Discard unused portion.</span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MYCAMINE 		
					</strong><br><span class="contentTableReg">micafungin sodium injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0469-3250</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MICAFUNGIN SODIUM</strong> (MICAFUNGIN) </td>
<td class="formItem">MICAFUNGIN SODIUM</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0469-3250-50</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021506</td>
<td class="formItem">12/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MYCAMINE 		
					</strong><br><span class="contentTableReg">micafungin sodium injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0469-3211</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>MICAFUNGIN SODIUM</strong> (MICAFUNGIN) </td>
<td class="formItem">MICAFUNGIN SODIUM</td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0469-3211-99</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021506</td>
<td class="formItem">12/01/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Astellas Pharma US, Inc.
							(605764828)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bc234dd7-5221-4a68-b153-aa0393c75bbf</div>
<div>Set id: bc234dd7-5221-4a68-b153-aa0393c75bbf</div>
<div>Version: 1</div>
<div>Effective Time: 20141114</div>
</div>
</div> <div class="DistributorName">Astellas Pharma US, Inc.</div></p>
</body></html>
